FDA OKs Milsaperidone (Bysanti) for Bipolar I Disorder and Schizophrenia
Megan Brooks February 23, 2026 The FDA has approved milsaperidone (Bysanti, Vanda Pharmaceuticals) as first-line treatment for acute manic or mixed episodes associated with bipolar I disorder and for the treatment of schizophrenia in adults. According to a company news release, milsaperidone is a “new chemical entity” in the atypical antipsychotic class of drugs. Milsaperidone is the […]
FDA OKs Milsaperidone (Bysanti) for Bipolar I Disorder and Schizophrenia Read More »
